Platinum-containing compounds exhibiting cytostatic...

Details Platinum-containing compounds exhibiting cytostatic... Platinum-containing compounds exhibiting cytostatic...

2007-04-24

2007-04-24

Nazario-Gonzalez, Porfirio (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C556S137000, C514S492000

Reexamination Certificate

active

11361435

ABSTRACT:
Platinum containing compounds exhibiting cytostatic activity, methods of synthesizing platinum-containing compounds exhibiting cytostatic activity pharmaceutical compositions comprising platinum containing compounds, and methods of using such compounds and compositions for treating cancer are disclosed.

REFERENCES:
patent: 3811444 (1974-05-01), Heller et al.
patent: 3962414 (1976-06-01), Michaels
patent: 3992518 (1976-11-01), Chien et al.
patent: 4066747 (1978-01-01), Capozza
patent: 4070347 (1978-01-01), Schmitt
patent: 4079038 (1978-03-01), Choi et al.
patent: 4083949 (1978-04-01), Benedikt
patent: 4093709 (1978-06-01), Choi et al.
patent: 4284579 (1981-08-01), Meischen et al.
patent: 4895935 (1990-01-01), Talebian et al.
patent: 4895936 (1990-01-01), Talebian et al.
patent: 4937358 (1990-06-01), Bitha et al.
patent: 4946954 (1990-08-01), Talebian et al.
patent: 4956459 (1990-09-01), Talebian et al.
patent: 4968826 (1990-11-01), Totani et al.
patent: 5091521 (1992-02-01), Kolar et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 7001888 (2006-02-01), Tidmarsh et al.
patent: 2003/0152518 (2003-08-01), Tidmarsh et al.
patent: 2004/0029815 (2004-02-01), Tidmarsh et al.
patent: 2006/0089341 (2006-04-01), Kratz et al.
patent: WO 1994/12285 (1994-06-01), None
patent: WO 2000/48572 (2000-08-01), None
patent: WO 2000/54588 (2000-09-01), None
patent: WO 2003/059149 (2003-07-01), None
patent: WO 2003/082301 (2003-10-01), None
patent: WO 2004/062604 (2004-07-01), None
patent: WO 2004/064734 (2004-08-01), None
patent: WO 2004/064735 (2004-08-01), None
patent: WO 2004/064736 (2004-08-01), None
patent: WO 2004/081181 (2004-09-01), None
patent: WO 2004/087075 (2004-10-01), None
patent: WO 2005/011931 (2005-02-01), None
patent: WO 2005/119261 (2005-12-01), None
patent: WO 2005/120498 (2005-12-01), None
Alderman, “A Review of cellulose Ethers in Hydrophilic Matrices dor Oral controlled-Release Dosage Forms,”Int. J. Pharm. Tech. & Prod. Mfr.1984, 5(3) 1-9.
Altomare et al., “Highly Water-Soluble Derivatives of Anaesthetic Agent Propofol: in vitro and invitro evaluation of cyclic amino esters,”European Journal of Pharmaceutical Sciences,2003, 20, 1, 17-26.
Anderson et al., “α-Amino Acid Phenolic Ester Derivatives: Novel Water-Soluble General Anesthetic Agents Which Allosterically Modulate GABAAReceptors,”J. Med. Chem.2001, 44, 3582-3591.
Arp, “Tumor Models: Assessing toxicity in Efficacy Studies,”Toxicol Pathol.,1999, 27(1), 121-122.
Balimane et al., “Involvement of multiple transporters in the oral absorption of nucleoside analogues,”Adv Drug Deliv Rev.Oct. 18, 1999;39(1-3):183-209.
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations,”Int. J. Pharm.1979, 2, 307.
Banaszcryk et al., “Propofol Phosphate, a Water-Soluble Propofol Prodrug: In Vivo Evaluation,”Anesth. Analg.2002, 95, 1285-1292.
Becker et al., “Human Thioredoxin Reductase Is Efficiently Inhabited by (2,2′:6′2″-Trepyridine) Platinum (II) Complexes. Possible Implications for Novel Antitumor Strategy,”J. Med. Chem.,2001, 44, 2784-2792.
Beilstein, Beilstein Handbook of Organic Chemistry, Beilsein Institute of Organic Chemistry, Frankfurt, Germany. vol. 27, Part 26, 1979.
Borgeat et al., “Preliminary Communication: Adjuvant Propofol Enables Better Control of Nausea and Emesid Secondary to Chemotherapy for Breast Cancer,”Can. J. Anaesth.1994, 1117-1119.
Borgeat et al., “Propofol improves patient comfort during cisplatin chemotherapy. A pilot study,”Oncology1993, 50, 456-459.
Brandel et al., “14-3-3 Protein Cerebrospinal Fluid Detection in Human Growth Hormone- Treated Creutzfeldt-Jakob Disease Patients,” Ann. Neurol. 2001, 49, 257-260.
Briggs et al., “An adverse reaction to the administration of disoprofol (Diprivan),”Anaesthesia1982, 37, 1099-1101.
Brooker et al., “Propofol Maintenance to Reduce Postoperatiove Emesis in Thyroidectomy Patients: A Group Sequential Comparison with Isoflurane/Nitrous Oxide,”Anaesth. Intensive Care1998, 26, 625-629.
Brown et al., “Role of Propofol in Refractory Status Epilepticus,”Pharmacother.1998, 32, 1053-1059.
Canetta et al., Carboplatin: Current Satatus and Future Prospects,Cancer Treat Rev.,1988, 15, Sup. B, 17-32.
Coleman et al., “Polymer Review: A Practical Guide to Polymer Miscibility,”Polymers,1990, 31, 1187-1231.
De Jonghe et al., “Further Evidence that Neurofilament Light Chain Gene Mutations Can Cause Charcot-Marie Tooth Disease Type 2E,” Ann. Neurol., 2001, 49-245-249.
De la Cruz et al., “The Effect of Propofol on Oxidative Stress in Platelets from Surgical Patients,”Anesth. Analg.1999, 89, 1050-1055.
During et al., “Controlled release of dopamine from a polymeric brain implant: in vivo characterization,” 1989,Ann. Neurol.25:351.
Feiser et al., “Reagents for Organic Synthesis,” vols. 1-17, Wiley Interscience, vol. 2, 2004.
Felmeister, “Powders,” Remington's Pharmaceutical Sciences, 1970, 14thEdition, 1626-1627, Mac Publishing Company, Easton, Pennsylvania.
Fincher, “Particle Size of Drugs and Its Relationship to Absorption and Activity,”J. Pharm. Sci.1968, 57, 1825-1835.
Gan et al., “Determination of Plasma Concentrations of Propofol Associated with 50% Reduction in Postoperative Nausea,”Anesthesiology,1997, 87, 779-784.
Gennaro, “Remington's Pharmaceutical Sciences,” Philadelphia College of Pharmacy and Science, 19th Edition, 1995.
Gonzalez et al., “Resolution of Acid Strength in Non-Aqueous Acid-Base Titrations,”Analytica Chimica Acta,1991, 281, 179-183.
Goodson, in “Medical Applications of Controlled Release,”supra,vol. 2, pp. 115-138 (1984).
Greene et al.Protective groups in Organic Chemistry, Wiley, 2nded., 1991.
Grothey, “Oxaliplatin-Safety Profile: Neurotoxicity,”Semin. Oncol.2003, 30, 4 Sup. 15, 5-13.
Hand et al., “Compound Heterozygous D90A and D96N SODI Mutations in a Recessive Amyotrophic Lateral Sclerosis Family,” Ann. Neurol, 2001, 49, 267-271.
Harrison et al.,Compendium of Synthetic Organic Methods,vols. 1-8, John Wiley and Sons, 1971-1996.
Hasan et al., “Comparison of the Effects of the Propofol and Thiopental on the Pattern of Maximal Electroshock Seizures in a Rat,”Pharmacol. Toxicol.1994, 74, 50-53.
Hashimoto et al., “Abnormal Activity in the Globus Pallidus in Off-Period Dystonia,”Ann. Neurol.,2001, 49, 242-245.
Hegedus et al.,Compendium of Organic Synthetic Methods,Wiley-Interscience Publication, vol. 3, 1977.
Hoes et al.,The Application of Drug-Polymer Conjugates in Chemotherapy,Drug Carrier Systems,1989, 9, 57-100.
Holtkamp et al., “Propofol in subanesthetic doses terminates status epilepticus in a rodent model,”Ann. Neurol.2001, 49, 260-263.
Howard et al., “Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,” 1989,J. Neurosurg.71:105-112.
Krusz et al., “Intravenous Propofol: Unique Effectiveness in Treating Intractable Migraine,”Headache2000, 40, 224-230.
Kuisma et al., “Propofol in Prewhospital Treatment of Convulsive Status Epilepticus,”Epilepsia1995, 36, 1241-1243.
Langer et al. “Medical Applications of Controlled Release,” , CRC Press, Boca Raton, Florida (1974).
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Relaease of Bioactive Agents: A Review,”J Macromol. Sci. Rev. Macromol Chem.1983, 23:61.
Langer, “New Method of Drug Delivery,” 1990,Science249:1527-1533.
Langley et al., “Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic,”Drugs1988, 35, 334-372.
Larock, “Comprehensive Organic Transformations: A Guide to Functional Group Preparations,” (VCH Publishers, 19

Affiliated with

Also associated with

Rating

Platinum-containing compounds exhibiting cytostatic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Platinum-containing compounds exhibiting cytostatic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platinum-containing compounds exhibiting cytostatic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3802475